Saudi Arabia Osteoporosis Drugs Market, By Type (Primary Osteoporosis & Secondary Osteoporosis), Drugs (Bisphosphonates, Monoclonal Antibodies, Hormone Therapy & Others), Drugs Type (Branded & Generic), Route of Administration (Injectable, Oral & Others), Gender (Female & Male), Age Group (Geriatrics, Adults & Pediatrics), End User (Hospitals, Specialty Clinics, Homecare & Others), Distribution Channel (Direct Tender, Retail Sales & Others) Industry Trends and Forecasts to 2029.
Saudi Arabia Osteoporosis Drugs Market Analysis and Insights
According to the International Osteoporosis Foundation (IOF), ‘osteoporosis, which means porous bone, is a disease in which the quality and density of bone are reduced. As bones become more fragile and porous, the risk of fracture is greatly increased. The loss of bone occurs progressively and silently. Often there are no symptoms until the first fracture occurs.
With age, some of the bone cells begin to dissolve bone matrix, the process is called resorption, while new bone cells deposit osteoid, and the process is called formation. This process is called as remodeling. For people with osteoporosis, bone loss outpaces the growth of new bone. Bones become brittle, porous and prone to fracture. Though osteoporosis fractures can occur in other bones also, but he most commonly osteoporosis fractures occurs at wrist, spine or the hip.
The different types of medications for osteoporosis are available in the market. The bisphosphonates are usually the first choice for treatment of osteoporosis. These includes Risedronate (Actonel), a weekly or monthly pill, Alendronate (Fosamax), a weekly pill, Zoledronic acid (Reclast), an annual IV infusion and Ibandronate (Boniva), a monthly pill or quarterly intravenous (IV) infusion.
Data Bridge Market Research analyses that the Saudi Arabia osteoporosis drugs market will grow at a CAGR of 2.9% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
Type (Primary Osteoporosis & Secondary Osteoporosis), Drugs (Bisphosphonates, Monoclonal Antibodies, Hormone Therapy & Others), Drugs Type (Branded & Generic), Route of Administration (Injectable, Oral & Others), Gender (Female & Male), Age Group (Geriatrics, Adults & Pediatrics), End User (Hospitals, Specialty Clinics, Homecare & Others), Distribution Channel (Direct Tender, Retail Sales & Others) |
|
Countries Covered |
Saudi Arabia |
|
Market Players Covered |
Eli Lilly and Company (U.S.), Novartis AG (Switzerland) , Amgen Inc. (U.S.), Tabuk pharmaceuticals (Saudi Arabia), SPIMACO (Saudi Arabia), Hikma Pharmaceuticals PLC (Jordan), Pfizer Inc. (U.S.) , Merck KGaA (Germany) , Apotex Inc. (Canada), ABIOGEN PHARMA S.p.A. (Italy), Sudair Pharma (Saudi Arabia), tadawipharma. (Saudi Arabia), Fresenius SE & Co. KGaA (Germany), Hayat Pharmaceutical Industries Co. PLC (Jordan), and SAJA Pharmaceuticals (Saudi Arabia) |
Osteoporosis Drugs Market Dynamics
Drivers
- Rise in Prevalence of Osteoporosis
Osteoporosis is a disease of bone which progresses due to the less bone mineral density and bone mass or due to some variation in the quality or structure of bone. Osteoporosis could increase the risk of fractures leading to broken bones due to decreased bone strength.
For instance,
- According to the International Osteoporosis Foundation, the prevalence of low bone mass is higher in Middle East then in western countries. Though osteoporosis affects both males and females, females are likely to develop osteoporosis than men
- Rise in geriatric population
As the geriatric population increases, osteoporosis and bone disorders are also rising among the older population. The aging population would refer to orthopedic centers which would increase the demand for osteoporosis treatment and hence is expected to as driver for the growth of Saudi Arabia osteoporosis drugs market.
Opportunities
- Government Initiatives
The osteoporosis is often referred to as the “silent disease” as bone loss is painless and gradual, and there are usually no symptoms to indicate a person is developing osteoporosis. So government is taking initiative early secreening, diagnosis and treatment of disease in the country. Therefor, acting as opportunity for the growth of the market in coming years.
Restraints/Challenges
However, the side effects associated with osteoporosis drugs and high treatment cost will hamper the growth of the osteoporosis durgs market in Saudi Arabia. Additionally, slow progress in restructuring the healthcare system will further challenge the market in the forecast period mentioned above.
This osteoporosis durgs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lab supplies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Osteoporosis is a disease of bone which progresses due to the less bone mineral density and bone mass or due to some variation in the quality or structure of bone. According to the Ministry of Health of Saudi Arabia, in 2018, the prevalence of osteoporosis was 37% in the population above the age of 50 years.
According to the international journal of research in medical sciences, in 2014, 82% of Saudi women patients had vitamin D deficiency. Only 21% of women were exposed to sunlight, 58% of the women had low BMD, out of which 18% with osteoporosis and 40% with osteopenia.
Osteoporosis drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohot multivariate statistical model for forecasting the market in growth period.
Post COVID-19 Impact on Lab Supplies Market
The COVID-19 has negatively affected the market. Lockdowns and isolations during pandemic complicates the disease management and medication adherence. The lack of access to healthcare facilities for routine treatment and medication administration will further impact the market.
Recent Development
- In September 2021, Hikma Pharmaceuticals PLC announced that it has agreed to acquire Custopharm Inc. to grow the injectable and generic business segments of the company. Custopharm has received 13 US FDA approvals, with four first-to-market Abbreviated New Drug Application (ANDA) approvals - including one with Competitive Generic Therapy (CGT) designation - and one novel 505(b)(2) NDA approval. This acquisition helped the company to increase its product portfolio and to further grow the overall revenue of the company.
Saudi Arabia Osteoporosis Drugs Market Scope
The osteoporosis drugs market is categorized into eight notable segments based on type, drugs, drugs type, route of administration, gender, age group, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Primary Osteoporosis
- Secondary Osteoporosis.
On the basis of type, Saudi Arabia osteoporosis drugs market is segmented into primary osteoporosis and secondary osteoporosis.
Drugs
- Bisphosphonates
- Monoclonal Antibodies
- Hormone Therapy
- Others
On the basis of drugs, Saudi Arabia osteoporosis drugs market is segmented into bisphosphonates, monoclonal antibodies, hormone therapy and others.
Drugs Type
- Branded
- Generic
On the basis of drugs type, Saudi Arabia osteoporosis drugs market is segmented into branded and generic.
Route of Administration
- Injectable
- Oral
- Others
On the basis of route of administration, Saudi Arabia osteoporosis drugs market is segmented into injectable, oral and others.
Gender
- Female
- Male
On the basis of gender, Saudi Arabia osteoporosis drugs market is segmented into female and male.
Age Group
- Geriatrics
- Adults
- Pediatrics
On the basis of age group, Saudi Arabia osteoporosis drugs market is segmented into geriatrics, adults and pediatrics.
End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end user, Saudi Arabia osteoporosis drugs market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, Saudi Arabia osteoporosis drugs market is segmented into direct tender, retail sales and others.
Pipeline Analysis
The pipeline analysis of osteoporosis drugs market includes various pipeline therapies such as Ibandronate, Risedronate Sodium, Ibandroante (Bonviva/Boniva), Strontium Ranelate. F. Hoffman-La Roche Ltd, Sanofi, Nycomed, Elly Lilly and Company and Nordic Biosciences A/S among others are involved in the development of potential drugs for the improvement of treatment of osteoporosis.
Competitive Landscape and Osteoporosis Drugs Market Share Analysis
The osteoporosis durgs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Saudi Arabia presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteoporosis durgs market.
Some of the major players operating in the Saudi Arabia osteoporosis drugs market are Eli Lilly and Company, Novartis AG, Amgen Inc., Tabuk pharmaceuticals, SPIMACO, Hikma Pharmaceuticals PLC, Pfizer Inc., Merck KGaA, Apotex Inc., ABIOGEN PHARMA S.p.A., Sudair Pharma, tadawipharma., Fresenius SE & Co. KGaA, Hayat Pharmaceutical Industries Co. PLC, and SAJA Pharmaceuticals among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
5 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PIPELINE ANALYSIS
6 REGULATIONS OF SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET
6.1 SUBMISSION
6.2 ASSESSMENT
7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, SUMMARY WRITE-UP
7.1 OVERVIEW
8 EPIDEMIOLOGY
8.1 EPIDEMIOLOGY - OSTEOPOROSIS
8.2 EPIDEMIOLOGY – RELATED INDICATIONS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN PREVALENCE OF OSTEOPOROSIS
9.1.2 RISE IN GERIATRIC POPULATION
9.2 RESTRAINTS
9.2.1 SIDE EFFECTS ASSOCIATED WITH OSTEOPOROSIS DRUGS
9.2.2 HIGH COST OF OSTEOPOROSIS TREATMENT
9.3 OPPORTUNITIES
9.3.1 GOVERNMENT INITIATIVES
9.3.2 RISE IN INCIDENCE OF SPORTS AND TRAUMA INJURIES
9.4 CHALLENGES
9.4.1 GAPS IN OSTEOPOROSIS PATIENT PATHWAY
10 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY TYPE
10.1 OVERVIEW
10.2 PRIMARY OSTEOPOROSIS
10.3 SECONDARY OSTEOPOROSIS
11 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS
11.1 OVERVIEW
11.2 BISPHOSPHONATES
11.2.1 ALENDRONATE
11.2.2 ZOLEDRONIC ACID
11.2.3 RISEDRONATE
11.2.4 IBANDRONATE
11.2.5 OTHERS
11.3 MONOCLONAL ANTIBODIES
11.3.1 DENOSUMAB
11.3.2 ROMOSOZUMAB
11.4 HORMONE THERAPY
11.4.1 PARATHYROID HORMONE (TERIPARATIDE)
11.4.2 ESTROGEN
11.4.2.1 CONJUGATED ESTROGENS
11.4.2.2 SELECTIVE ESTROGEN RECEPTOR MODULATORS
11.4.2.3 ESTERIFIED ESTROGENS
11.4.2.4 OTHERS
11.4.3 CALCITONIN
11.4.4 OTHERS
11.5 OTHERS
12 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 BRANDED
12.3 GENERIC
13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 INJECTABLE
13.3 ORAL
13.3.1 TABLETS
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 OTHERS
14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY GENDER
14.1 OVERVIEW
14.2 FEMALE
14.3 MALE
15 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY AGE GROUP
15.1 OVERVIEW
15.2 GERIATRICS
15.3 ADULTS
15.4 PEDIATRICS
16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CLINICS
16.4 HOMECARE
16.5 OTHERS
17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 RETAIL SALES
17.3.1 HOSPITAL PHARMACY.
17.3.2 ONLINE RETAIL CHANNELS.
17.3.3 OTHER PHARMACY STORES.
17.4 OTHERS.
18 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: SAUDI ARABIA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 AMGEN INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENT
20.1.4.1 PRODUCT LAUNCH
20.2 ELI LILLY AND COMPANY
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 HIKMA PHARMACEUTICALS PLC
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENT
20.3.4.1 ACQUISITION
20.4 NOVARTIS AG
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
20.4.4.1 ACQUISITION
20.5 PFIZER INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 ABIOGEN PHARMA S.P.A
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.6.3.1 PRODUCT LAUNCH
20.7 APOTEX INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.7.3.1 PRODUCT LAUNCH
20.8 FRESENIUS SE & CO. KGAA
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.8.4.1 INITIATION OF PHASE 3 TRIALS
20.9 HAYAT PHARMACEUTICAL INDUSTRIES CO. PLC
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.9.3.1 NEW PRODUCT LAUNCH
20.1 MERCK KGAA
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 SAJA PHARMACEUTICLAS
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 SPIMACO
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 SUDAIR PHARMA
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.13.3.1 ACQUISITION
20.14 TABUK PHARMACEUTICALS
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.14.3.1 ACQUISITION
20.15 TADAWIPHARMA
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tablas
TABLE 1 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PIPELINE ANALYSIS
TABLE 2 PROJECTED NUMBER OF OSTEOPOROSIS PATIENTS, BY COUNTRY, 2021-2026, (IN UNITS)
TABLE 3 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, DIAGNOSIS RATE, 2021-2026, (IN %)
TABLE 4 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, TREATMENT RATE, 2021-2026, (IN %)
TABLE 5 COST ESTIMATION OF PATIENTS WITH OSTEOPOROSIS
TABLE 6 ESTIMATED COST OF MEDICATIONS FOR THE TREATMENT OF OSTEOPOROSIS
TABLE 7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 9 SAUDI ARABIA BISPHOSPHONATES IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 10 SAUDI ARABIA MONOCLONAL ANTIBODIES IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 11 SAUDI ARABIA HORMONE THERAPY IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 12 SAUDI ARABIA ESTROGEN IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 15 SAUDI ARABIA ORAL IN OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 18 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 19 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 20 SAUDI ARABIA RETAIL SALES IN OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
Lista de figuras
FIGURE 1 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: SEGMENTATION
FIGURE 2 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: DROC ANALYSIS
FIGURE 4 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: SEGMENTATION
FIGURE 11 RISE IN PREVALENCE OF OSTEOPOROSIS AND GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 PRIMARY OSTEOPOROSIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET IN 2022 & 2029
FIGURE 13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PREVALENCE RATE AGED BETWEEN 50-79 YEARS, 2020
FIGURE 14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PROJECTED NUMBER OF OSTEOPOROSIS PATIENTS, (2021-2026)
FIGURE 15 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, DIAGNOSIS RATE, (2020-2026)
FIGURE 16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, TREATMENT RATE, (2020-2026)
FIGURE 17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, ADHERENCE RATE
FIGURE 18 OSTEOPOROSIS RELATED INDICATIONS, SAUDI ARABIA, 2020
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET
FIGURE 20 ANNUAL FEMUR FRACTURE RATE IN SAUDI ARABIAN POPULATION, PER 1,000,000 PERSONS-YEARS
FIGURE 21 OSTEOPOROSIS PATIENT JOURNEY IN KINGDOM OF SAUDI ARABIA
FIGURE 22 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, 2021
FIGURE 23 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 24 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 25 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 26 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, 2021
FIGURE 27 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, 2022-2029 (USD MILLION)
FIGURE 28 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, CAGR (2022-2029)
FIGURE 29 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 30 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, 2021
FIGURE 31 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, 2022-2029 (USD MILLION)
FIGURE 32 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, CAGR (2022-2029)
FIGURE 33 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 34 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 35 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 36 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 37 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 38 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, 2021
FIGURE 39 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, 2022-2029 (USD MILLION)
FIGURE 40 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, CAGR (2022-2029)
FIGURE 41 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 42 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, 2021
FIGURE 43 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 44 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 45 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 46 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, 2021
FIGURE 47 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 48 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 49 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 50 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 51 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 52 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 53 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 54 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: COMPANY SHARE 2021 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
